Abbott commences endometriosis oral drug Phase 3 study

The 24-week, double-blind, multinational, placebo-controlled, randomized study is designed to assess the safety and efficacy of Elagolix in 875 women, age 18 to 49, suffering with moderate-to-severe endometriosis-associated pain.

Elagolix is an oral gonadotropin-releasing hormone antagonist designed to treat endometriosis in female patients.

Abbott global pharmaceutical R&D pain, respiratory and metabolic development divisional vice president Rita Jain said, "We are pleased to announce that the Phase 3 trial has begun screening for enrollment."

The company said a second pivotal Phase 3 study is planned with an new drug application filing targeted in 2016.